Literature DB >> 6608404

Defective interleukin-1 production by monocytes from patients with malignant disease. Interferon increases IL-1 production.

J Herman, M C Kew, A R Rabson.   

Abstract

Interleukin-1 (IL-1) production by monocytes of patients with various forms of malignant disease was measured after activating the cells with either lipopolysaccharide or malignant K562 cells. Monocytes from all the patients with large tumour masses, including 10 patients with hepatocellular carcinoma, produced considerably less IL-1 than controls or patients with small tumour burdens. After treating control or patient monocytes with human leucocyte interferon for 1 h prior to activation, IL-1 production was markedly improved. Depressed IL-1 production is, therefore, a further aberration in mononuclear function observed in patients with cancer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608404     DOI: 10.1007/bf00205426

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  Molecular mechanisms in tumor-cell killing by activated macrophages.

Authors:  D O Adams; C F Nathan
Journal:  Immunol Today       Date:  1983-06

2.  Spontaneous cytotoxicity mediated by human monocyte-macrophages against human fibroblasts infected with herpes simplex virsu--augmentation by interferon.

Authors:  T L Stanwick; D E Campbell; A J Nahmias
Journal:  Cell Immunol       Date:  1980-08-01       Impact factor: 4.868

3.  Interferon-induced enhancement of macrophage Fc receptor expression: beta-interferon treatment of C3H/HeJ macrophages results in increased numbers and density of Fc receptors.

Authors:  S N Vogel; D S Finbloom; K E English; D L Rosenstreich; S G Langreth
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

4.  Cooperation between mononuclear phagocytes and lymphocytes in immunity.

Authors:  E R Unanue
Journal:  N Engl J Med       Date:  1980-10-23       Impact factor: 91.245

5.  The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity.

Authors:  R A Dempsey; C A Dinarello; J W Mier; L J Rosenwasser; M Allegretta; T E Brown; D R Parkinson
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

6.  Defective Fc receptor-mediated phagocytosis in C3H/HeJ macrophages. I. Correction by lymphokine-induced stimulation.

Authors:  S N Vogel; D L Rosenstreich
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

7.  A method for dinitrochlorobenzene contact sensitization. A clinicopathological study.

Authors:  W J Catalona; P T Taylor; A S Rabson; P B Chretien
Journal:  N Engl J Med       Date:  1972-02-24       Impact factor: 91.245

8.  Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; B A Torres; H M Johnson; P W Gray
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  Bidirectional amplification of macrophage-lymphocyte interactions: enhanced lymphocyte activation factor production by activated adherent mouse peritoneal cells.

Authors:  M S Meltzer; J J Oppenheim
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

10.  Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony-stimulating factors.

Authors:  R N Moore; J J Oppenheim; J J Farrar; C S Carter; A Waheed; R K Shadduck
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

View more
  15 in total

1.  Effects of L2C leukemia on macrophage-mediated responses.

Authors:  D P Collins
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Effect of interferon on the induction of human monocyte secretion of interleukin-1 activity.

Authors:  R C Newton
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

Review 3.  Expression of the genes of interferons and other cytokines in normal and diseased tissues of man.

Authors:  M G Tovey
Journal:  Experientia       Date:  1989-06-15

4.  Defective interleukin-1 production by natural killer cells of patients with cancer.

Authors:  J Herman; M C Kew; A R Rabson
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  The effect of RU 41.740 (Biostim) on the production of interleukin-1 by monocytes and enriched large granular lymphocytes in normals and patients with hepatocellular carcinoma.

Authors:  J Herman; M C Kew; A R Rabson
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Viral reactivation as a cause of unexplained fever in patients with progressive metastatic breast cancer.

Authors:  S Rasoul-Rockenschaub; C C Zielinski; C Müller; E Tichatschek; T Popow-Kraupp; C Kunz
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Defective interleukin-1 production in a familial monocyte disorder with a combined abnormality of mobility and phagocytosis-killing.

Authors:  A Komiyama; M Ichikawa; H Kanda; K Aoyama; K Yasui; M Yamazaki; H Kawai; Y Miyagawa; T Akabane
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

8.  Production of interleukin-1 and tumour necrosis factor in non-Hodgkin's lymphoma patients.

Authors:  K Jhaver; A De; S Advani; J Nadkarni
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis.

Authors:  C Aime; S Cohen-Kaminsky; S Berrih-Aknin
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

Review 10.  An update on human interleukin-1: from molecular biology to clinical relevance.

Authors:  C A Dinarello
Journal:  J Clin Immunol       Date:  1985-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.